Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Naturally Produced Cannabinoids for Neuroprotection From Concussion

14 juillet 2026 mis à jour par: University of Regina

Naturally Produced Cannabinoids for Pain Management and Neuroprotection From Concussion During Participation in Contact Sports: Neuroprotection

The goal of this double-blind, placebo-controlled, cross over study is to learn about the neuroprotective properties of a broad-spectrum cannabinoid formulation in normal healthy adults engaged in elite contact sport competition.

The main question it aims to answer :

• Is the broad-spectrum cannabinoid formulation neuroprotective for athletes participating in competitive contact sports? Can this formulation facilitate recovery in those who suffer from concussion by reducing inflammation and/or reduce the number of concussions sustained without adverse physiological and psychological dysfunction when administered daily?

Participants will:

  • be given a broad-spectrum cannabinoid gel capsule or a placebo twice daily.
  • have blood samples taken to analyze pharmacokinetics and pharmacodynamics of cannabinoid metabolites, liver function, complete blood count and blood differential, inflammatory biomarkers and genetic analysis
  • have stool samples collected for gut microbiome analysis;
  • undergo testing sessions, which will include psychological and health questionnaires, equipment to record signals from the brain and heart, and safety laboratory tests.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

This research project will be a Phase II clinical trial to test the neuroprotective properties of the broad spectrum cannabinoid formulation. Specifically, the investigators will assess the neuroprotective properties of the cannabinoid formulation during a competitive season of contact football or ice hockey in elite university varsity athletics.

The primary research hypothesis is that the cannabinoid formulation will be neuroprotective for athletes in a competitive university varsity football or hockey season and will help to reduce the number of concussions sustained by the athletes in comparison to previous seasons, and in comparison, to the Placebo group. Furthermore, it is expected that the cannabinoid formulation will facilitate recovery in those who do suffer from a concussion by reducing inflammation.

The secondary hypotheses are:

  1. The cannabinoid formulation will result in improved physiological and psychological performance throughout the competitive season compared to placebo.
  2. The inflammatory markers will be reduced in those taking the cannabinoid formulation as compared to those taking placebo.

This research study is unique and important for several reasons:

  1. The investigators will conduct the first ever randomized controlled trial to understand the neuroprotective effects of a cannabinoid formulation designed to mitigate concussion in a population at a heightened risk of concussion and understand if recovery with the cannabinoid formulation more rapidly improves concussion symptoms.
  2. The investigators will use an integrated approach to examine the effects of our cannabinoid formulation on qualitative and quantitative outcome measures including clinical, physiological, neurophysiological, biopsychological, and functional motor performance.
  3. The cannabinoid levels will be studied in the blood to assess the pharmacokinetics and pharmacodynamics of these compounds and correlate these with our cerebrovascular, cardiovascular and neurophysiological indices.
  4. The investigators will genotype participant blood samples for known polymorphisms (single nucleotide polymorphisms, copy number variants, etc.) and relate our findings to observed drug effect in study participants.
  5. The investigators will investigate the effects of the cannabinoid formulation on the gut microbiome from stool samples, which has been implicated to have an effect on concussion.

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Elizabeth S. Thompson, Ph.D
  • Numéro de téléphone: 708-774-7698
  • E-mail: e.thompson@usask.ca

Lieux d'étude

  • Canada
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4S-0A2
        • Recrutement
        • University of Regina
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Healthy male adults between 19-35 years of age that compete in contact sport athletics.
  • Participants with no known cerebrovascular or cardiovascular complications.
  • Participants will not be habitual recreational users of cannabis (i.e., <1 day/week) or tobacco users.
  • Participants that agree not use any other cannabis or tobacco products while enrolled in the study.
  • Participants willing to provide a list of any prescription medications they are taking.
  • Ability to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, perceptual-cognitive, and functional motor skills laboratory tests.
  • Participants who are capable of giving signed informed consent.

Exclusion Criteria:

  • Female.
  • Must not travel to the USA during study period; USA laws do not permit cross border with cannabis products.
  • Use of cannabis-based therapy within 2 months (participants who have previously used a cannabis based therapy may be included if they have a 2-month period without use of cannabis-based therapy prior to enrollment in the study).
  • Participants with any level of cannabis in their blood samples when sampled at the commencement of the study will be excluded.
  • Participants that are being medically supervised for anxiety, depression, Post Traumatic Stress Disorder (PTSD), mood disorder, psychotic disorders or any cerebrovascular and cardiovascular complications.
  • Participants who are taking prescription medications such as psychotropic medications with serotonergic activity, including Selective Serotonin Reuptake Inhibitors (i.e. Fluoxetine), Tricyclic Antidepressants (i.e. Elavil, Nortriptyline) and Atypical Neuroleptics (i.e. Risperidone, Seroquel).
  • Initiation or dosage change of oral or injected steroids within 3 months.
  • Allergy or known intolerance to any of the compounds within the study preparation.
  • Unable to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, and functional motor skills laboratory tests.
  • Inability of study participants to attend assessments on a regular basis at the pre-determined times, or failure to take the drug daily.
  • Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator).
  • If they already have a concussion at the time of starting the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Broad sprectrum cannabinoid gel capsule
Gel capsule containing broad spectrum cannabinoid formulation
Médicament: Broad spectrum cannabinoid formulation
Broad spectrum cannabinoid formulation gel capsule
Comparateur placebo: Placebo
Placebo gel capsule
Autre: Placebo gel capsule
Placebo gel capsule will have MCT oil only, no active ingredient

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Plasma cannabidiol (CBD) metabolite concentration
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in plasma concentrations of cannabidiol (CBD) and CBD metabolites measured from venous blood samples.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Plasma tetrahydrocannabinol (THC) metabolite concentration
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in plasma concentrations of tetrahydrocannabinol (THC) and THC metabolites measured from venous blood samples.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Inflammatory biomarker concentrations in blood
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in blood concentrations of inflammatory and neurobiological biomarkers, including tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), brain-derived neurotrophic factor (BDNF), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), measured from venous blood samples.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Liver function laboratory values
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in liver function laboratory values, including total protein, albumin, bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), measured from venous blood samples at a provincial accredited laboratory.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Hematology and clinical chemistry laboratory values
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in complete blood count, blood differential, sodium, potassium, chloride, total CO2, calcium, magnesium, phosphate, and creatinine measured from venous blood samples.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Cerebral blood flow velocity
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in cerebral blood flow velocity in the middle cerebral artery and posterior cerebral artery measured by transcranial Doppler ultrasound.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Cerebral oxygenation
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in cerebral oxygenation in the right and left prefrontal cortex measured by functional near-infrared spectroscopy.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Continuous blood pressure
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in continuous blood pressure measured using Finapres Nova finger photoplethysmography.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Changes in cardiovascular physiology
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in cardiac cycle timing parameters measured using seismocardiography (SCG).
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Officially diagnosed concussion incidence
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Number of officially diagnosed concussions sustained by participants during the study period.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Cortical inhibition measured by transcranial magnetic stimulation (TMS)
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Monitor excitatory:inhibitory ratio of neurotransmitter activity via transcranial magnetic stimulation (TMS) including cortical silent period and short-interval intracortical inhibition.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Brief Pain Inventory-Short Form Pain Interference score
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).

Change in pain interference measured using the Brief Pain Inventory-Short Form (BPI-SF) Pain Interference Scale. The Pain Interference score is calculated as the mean of seven items assessing interference with general activity, mood, walking ability, work, relationships, sleep, and enjoyment of life. Scores range from 0 to 10, with higher scores indicating greater pain interference.

Units: 0-10 scale score
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Brief Pain Inventory-Short Form Pain Severity Score
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).

Change in pain severity measured using the Brief Pain Inventory-Short Form (BPI-SF) Pain Severity Scale. The Pain Severity score is calculated as the mean of four items (worst, least, average, and current pain). Scores range from 0 to 10, with higher scores indicating greater pain severity.

Units: 0-10 scale score
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
McGill Pain Questionnaire-Short Form pain score
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).

Change in pain measured using the Short-Form McGill Pain Questionnaire (SF-MPQ). The questionnaire includes 15 pain descriptors (11 sensory and 4 affective), each rated from 0 (none) to 3 (severe). The total score ranges from 0 to 45, with higher scores indicating greater pain severity.

Units: 0-45 scale score
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Numeric Rating Scale for Pain score
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants.

Change in pain intensity measured using the Numeric Rating Scale (NRS). Participants rate their pain on an 11-point scale from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity.

Units: 0-10 scale score
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants.
Pain Behaviour Measurement score
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).

Change in observed pain behavior measured using the Pain Behaviour Measurement (PBM) system. The PBM quantifies the frequency and/or duration of observed pain-related behaviors during standardized assessment. Higher scores indicate greater pain-related behavior.

Units: PBM score
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in Leeds Sleep Evaluation Questionnaire (LSEQ) score
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).

The LSEQ is a validated 10-item questionnaire that assesses getting to sleep, quality of sleep, awakening from sleep, and behaviour following wakefulness. Scores are reported on a 0 to 100 visual analogue scale, with higher scores indicating better perceived sleep quality and sleep-related functioning.

Units: 0-100 scale score
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Vertical Jump Performance
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in vertical jump height measured using the Vertec vertical jump test.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Adverse Event Incidence
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Number of participants experiencing adverse events, including sleepiness, lethargy, irritability, nausea, vomiting, and diarrhea.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Stool microbiome composition
Délai: From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Change in gastrointestinal microbiome composition assessed using stool sample analysis performed using standard laboratory methods.
From enrollment to end of treatment crossover (4 weeks for football participants or 8 weeks for hockey participants).
Identification of genetic markers associated with cannabinoid metabolism
Délai: Baseline assessment.
Single nucleotide polymorphisms and copy number variants associated with inter-individual metabolic differences in cannabinoid metabolism identified using next-generation sequencing.
Baseline assessment.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

University of Regina

Collaborateurs

National Football League

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 juin 2026

Achèvement primaire (Estimé)

1 mars 2027

Achèvement de l'étude (Estimé)

1 mars 2027

Dates d'inscription aux études

Première soumission

23 juin 2026

Première soumission répondant aux critères de contrôle qualité

14 juillet 2026

Première publication (Réel)

21 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

14 juillet 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • Bio3456
  • NFL-NEUROPROTECTION-02 (Autre identifiant: University of Regina)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner